【摘要】：目的通過觀察自擬桑艾杜藤湯足浴對(duì)改善糖尿病下肢周圍神經(jīng)病變中醫(yī)證候、臨床癥狀、體征、運(yùn)動(dòng)及感覺神經(jīng)傳導(dǎo)速度的效果,評(píng)價(jià)其臨床療效及安全性。方法隨機(jī)選取2014年12月至2016年3月就診于唐山市中醫(yī)醫(yī)院內(nèi)分泌科符合糖尿病下肢周圍神經(jīng)病變?cè)\斷標(biāo)準(zhǔn)及納入標(biāo)準(zhǔn)的108例病人作為試驗(yàn)觀察對(duì)象,將108例病人隨機(jī)分為對(duì)照一組、對(duì)照二組及治療組。對(duì)照一組予甲鈷胺片(衛(wèi)材中國藥業(yè)有限公司),0.5mg/次,口服,3次/日。對(duì)照二組在對(duì)照一組治療基礎(chǔ)上,予40℃溫水恒溫浸泡雙足,40分鐘/次,1次/日。治療組在對(duì)照一組治療基礎(chǔ)上,予自擬桑艾杜藤湯足浴治療(水溫、水量、浸泡時(shí)間及方法均與對(duì)照二組相同)。三組均以30天為1個(gè)療程,監(jiān)測(cè)治療前后3組中醫(yī)證候積分、Toronto評(píng)分(癥狀分、反射分、感覺試驗(yàn)分)、脛神經(jīng)運(yùn)動(dòng)傳導(dǎo)速度(MNCV1)、腓總神經(jīng)運(yùn)動(dòng)傳導(dǎo)速度(MNCV2)、脛神經(jīng)感覺傳導(dǎo)速度(SNCV1),從而評(píng)判其臨床療效。結(jié)果研究共納入病例108例,8例未堅(jiān)持1/2療程。實(shí)際完成病例共100例,對(duì)照一組32例,對(duì)照二組35例,治療組33例。1三組總體療效比較:治療組總有效率為87.9%,對(duì)照二組總有效率為48.6%,對(duì)照一組總有效率為25.0%。三組療效比較,治療組療效明顯優(yōu)于對(duì)照一組、對(duì)照二組(P0.05)。2中醫(yī)證候積分比較:治療前三組中醫(yī)證候積分之間無顯著差異(P0.05),無統(tǒng)計(jì)學(xué)意義。治療后三組中醫(yī)證候積分均有明顯改善(P0.05);治療組積分改善情況優(yōu)于對(duì)照一組和對(duì)照二組,有顯著差異(P0.05),有統(tǒng)計(jì)學(xué)意義。3 Toronto評(píng)分比較:治療前三組Toronto評(píng)分無顯著差異(P0.05),無統(tǒng)計(jì)學(xué)意義。治療后三組Toronto評(píng)分均較治療前降低(P0.05),說明三組治療均有效;治療組Toronto評(píng)分降低情況優(yōu)于對(duì)照一組和對(duì)照二組,有顯著差異(P0.05),有統(tǒng)計(jì)學(xué)意義。說明治療組在改善臨床癥狀、體征方面優(yōu)于對(duì)照一組、對(duì)照二組。4神經(jīng)傳導(dǎo)速度比較:治療前三組神經(jīng)傳導(dǎo)速度之間無顯著差異(P0.05),無統(tǒng)計(jì)學(xué)意義。治療后三組MNCV1、MNCV2、SNCV1均較治療前提高(P0.05),說明三組治療均有效;治療組神經(jīng)傳導(dǎo)速度提高情況優(yōu)于對(duì)照一組和對(duì)照二組,有顯著差異(P0.05),有統(tǒng)計(jì)學(xué)意義。說明治療組在提高神經(jīng)傳導(dǎo)速度方面優(yōu)于對(duì)照一組、對(duì)照二組。結(jié)論自擬桑艾杜藤湯足浴治療能較好地改善糖尿病下肢周圍神經(jīng)病變患者臨床癥狀、體征,提高運(yùn)動(dòng)及感覺神經(jīng)傳導(dǎo)速度,緩解中醫(yī)證候。且該方法治療中未出現(xiàn)不良反應(yīng),說明本方法安全有效,值得臨床應(yīng)用。
[Abstract]:Objective to evaluate the clinical efficacy and safety of Sanituteng decoction in improving TCM syndromes, clinical symptoms, signs, motor and sensory nerve conduction velocities of diabetic peripheral neuropathy of lower extremities. Methods 108 patients with diabetic peripheral neuropathy were randomly selected from Department of Endocrinology, Tangshan traditional Chinese Medicine Hospital from December 2014 to March 2016. 108 patients were randomly divided into control group, control group and treatment group. The control group was treated with mecobalamin tablets (Eisai China Pharmaceutical Co., Ltd.), 0.5mg/, orally, three times a day. On the basis of the treatment in the control group, the two groups were soaked in 40 鈩，

本文編號(hào)：2300968